e-Newsletter April 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Search results
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
Joining us for an "Ask the Expert" session is Dr Roly Megaw.
Our community are the reason we are able to continue supporting those with inherited sight-loss conditions through research and practical support.
Mirugen – Unlocking the Power of Retina Regeneration
Martin's son was diagnosed with Stargardt’s at a young age which has led Martin to take a close interest in the progress of research into Retinal disease.
These frequently asked questions should provide a response for most of the queries you might raise.
Our Medical Advisory Board (MAB) advises our Board of Trustees in order that they can approve grants for research projects.
Many inherited sight loss conditions occur when cells in the retina, which is the light-sensitive region at the back of the eye, deteriorate in an unpredictable way. These conditions are often referred to as inherited retinal dystrophies.